Enveric Biosciences Inc (ENVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.45M
Last updated: Nov 17, 2026 at 4:10 PM ET
Enveric Biosciences Inc (ENVB) Stock Chart
Enveric Biosciences (ENVB) has a latest price of $1.41 on Nov 17, 2026, 89.4% below its 52-week high of $13.25. Its price fell 73.3% over the past 12 months. The month-end price fell 100.0% since Dec 2016, a compound annual decline of 75.5%.
Price Chart
From Dec 2016 to Oct 2026, its highest month-end close was $2,024,797.93 in Jun 2017 and its lowest $1.37 in Aug 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ENVB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ENVB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 7.6%, and over 6 months it fell 33.2%. The month-end price fell 99.5% over the 3 years through Oct 2026, a compound annual decline of 83.4%.
| Period | Change |
|---|---|
| 1 month | +1.4% |
| 3 months | +7.6% |
| 6 months | -33.2% |
| 12 months | -73.3% |
| 12 months, with dividends | -73.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -99.5% | -83.4% |
| 5 years | -100.0% | -84.5% |
| Since Dec 2016 | -100.0% | -75.5% |
Price by Year
Its best calendar year was 2020, when the price fell 34.5%, and its weakest was 2022, when it fell 95.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.43 | -60.6% |
| 2025 | $3.63 | -94.4% |
| 2024 | $64.51 | -72.4% |
| 2023 | $233.98 | -37.5% |
| 2022 | $374.36 | -95.5% |
| 2021 | $8,369.16 | -37.2% |
| 2020 | $13,318.67 | -34.5% |
| 2019 | $20,337.97 | -48.2% |
| 2018 | $39,236.08 | -94.4% |
| 2017 | $697,430.40 | -52.4% |
Trading Range
The price is 4.0% below its 50-day average of $1.47 and 25.0% below its 200-day average of $1.88.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.41 | |
| 52-week high | $13.25 | -89.4% |
| 52-week low | $1.17 | +20.5% |
| 50-day average | $1.47 | -4.0% |
| 200-day average | $1.88 | -25.0% |
Price Risk
Over 3 years, its largest fall from a peak was 99.6%.
| Measure | Value |
|---|---|
| 1-year beta | 0.77 |
| Largest fall, 1 year | -87.7% |
| Largest fall, 3 years | -99.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ENVB
What is ENVB's 1-year price change?
Enveric Biosciences's price fell 73.3% over the past 12 months. With dividends included, the 12-month total return was -73.3%.
What is ENVB's 5-year price change?
Enveric Biosciences's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 84.5%. These figures leave out dividends.
What is ENVB's 52-week high and low?
Enveric Biosciences's 52-week high is $13.25 and its 52-week low is $1.17. Its latest price of $1.41 on Nov 17, 2026 is 89.4% below the high.
What is ENVB's beta?
Enveric Biosciences's 1-year beta against the S&P 500 is 0.77, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 87.7%.
Is the ENVB chart free?
Yes. Advanced Charting for ENVB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ENVB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors